Research to practice

Adoption of naltrexone in alcoholism treatment

Cindy Parks Thomas, Stanley S. Wallack, Sue Lee, Dennis McCarty, Robert Swift

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

Naltrexone, a prescription medication, was approved in December 1994 as an adjunct to counseling in treatment of alcoholism and alcohol abuse, representing the first new medication for alcoholism in several decades. Initial controlled trials indicated that it is effective in preventing relapse, while later trials show mixed results. Although many physicians and others treating alcoholism have found naltrexone to be very helpful in treatment, it is still a technology that has not been used widely. In this study, we examine which clinicians have adopted naltrexone into practice for what reasons, and what clinical and nonclinical factors acted as barriers to its use. In our mail survey of alcoholism treatment clinicians, 80% of physicians and 45% of nonphysicians report prescribing or recommending naltrexone at least rarely, but only 15% of physicians, even among addiction specialists, prescribe naltrexone often. The strongest barriers to adoption of naltrexone were financing and inadequate knowledge about the medication, followed by lack of sufficient evidence regarding effectiveness. Clinicians were most likely to adopt naltrexone if they were affiliated with treatment programs that actively promoted its use. We conclude that in order for a new substance abuse treatment medication to be widely adopted in clinical practice, information about it must be properly directed, clinicians must be convinced of its effectiveness, it must be adequately financed, and the treatment organizations in which clinicians work must promote its use.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalJournal of Substance Abuse Treatment
Volume24
Issue number1
DOIs
StatePublished - Jan 2003

Fingerprint

Naltrexone
Alcoholism
Research
Physicians
Therapeutics
Postal Service
Substance-Related Disorders
Prescriptions
Counseling
Organizations
Technology
Recurrence

Keywords

  • Alcoholism treatment
  • Diffusion
  • Medication
  • Naltrexone
  • Prescribing

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Research to practice : Adoption of naltrexone in alcoholism treatment. / Thomas, Cindy Parks; Wallack, Stanley S.; Lee, Sue; McCarty, Dennis; Swift, Robert.

In: Journal of Substance Abuse Treatment, Vol. 24, No. 1, 01.2003, p. 1-11.

Research output: Contribution to journalArticle

Thomas, Cindy Parks ; Wallack, Stanley S. ; Lee, Sue ; McCarty, Dennis ; Swift, Robert. / Research to practice : Adoption of naltrexone in alcoholism treatment. In: Journal of Substance Abuse Treatment. 2003 ; Vol. 24, No. 1. pp. 1-11.
@article{8cc3da21be1d46249c9fb8c57f8e8f02,
title = "Research to practice: Adoption of naltrexone in alcoholism treatment",
abstract = "Naltrexone, a prescription medication, was approved in December 1994 as an adjunct to counseling in treatment of alcoholism and alcohol abuse, representing the first new medication for alcoholism in several decades. Initial controlled trials indicated that it is effective in preventing relapse, while later trials show mixed results. Although many physicians and others treating alcoholism have found naltrexone to be very helpful in treatment, it is still a technology that has not been used widely. In this study, we examine which clinicians have adopted naltrexone into practice for what reasons, and what clinical and nonclinical factors acted as barriers to its use. In our mail survey of alcoholism treatment clinicians, 80{\%} of physicians and 45{\%} of nonphysicians report prescribing or recommending naltrexone at least rarely, but only 15{\%} of physicians, even among addiction specialists, prescribe naltrexone often. The strongest barriers to adoption of naltrexone were financing and inadequate knowledge about the medication, followed by lack of sufficient evidence regarding effectiveness. Clinicians were most likely to adopt naltrexone if they were affiliated with treatment programs that actively promoted its use. We conclude that in order for a new substance abuse treatment medication to be widely adopted in clinical practice, information about it must be properly directed, clinicians must be convinced of its effectiveness, it must be adequately financed, and the treatment organizations in which clinicians work must promote its use.",
keywords = "Alcoholism treatment, Diffusion, Medication, Naltrexone, Prescribing",
author = "Thomas, {Cindy Parks} and Wallack, {Stanley S.} and Sue Lee and Dennis McCarty and Robert Swift",
year = "2003",
month = "1",
doi = "10.1016/S0740-5472(02)00319-7",
language = "English (US)",
volume = "24",
pages = "1--11",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Research to practice

T2 - Adoption of naltrexone in alcoholism treatment

AU - Thomas, Cindy Parks

AU - Wallack, Stanley S.

AU - Lee, Sue

AU - McCarty, Dennis

AU - Swift, Robert

PY - 2003/1

Y1 - 2003/1

N2 - Naltrexone, a prescription medication, was approved in December 1994 as an adjunct to counseling in treatment of alcoholism and alcohol abuse, representing the first new medication for alcoholism in several decades. Initial controlled trials indicated that it is effective in preventing relapse, while later trials show mixed results. Although many physicians and others treating alcoholism have found naltrexone to be very helpful in treatment, it is still a technology that has not been used widely. In this study, we examine which clinicians have adopted naltrexone into practice for what reasons, and what clinical and nonclinical factors acted as barriers to its use. In our mail survey of alcoholism treatment clinicians, 80% of physicians and 45% of nonphysicians report prescribing or recommending naltrexone at least rarely, but only 15% of physicians, even among addiction specialists, prescribe naltrexone often. The strongest barriers to adoption of naltrexone were financing and inadequate knowledge about the medication, followed by lack of sufficient evidence regarding effectiveness. Clinicians were most likely to adopt naltrexone if they were affiliated with treatment programs that actively promoted its use. We conclude that in order for a new substance abuse treatment medication to be widely adopted in clinical practice, information about it must be properly directed, clinicians must be convinced of its effectiveness, it must be adequately financed, and the treatment organizations in which clinicians work must promote its use.

AB - Naltrexone, a prescription medication, was approved in December 1994 as an adjunct to counseling in treatment of alcoholism and alcohol abuse, representing the first new medication for alcoholism in several decades. Initial controlled trials indicated that it is effective in preventing relapse, while later trials show mixed results. Although many physicians and others treating alcoholism have found naltrexone to be very helpful in treatment, it is still a technology that has not been used widely. In this study, we examine which clinicians have adopted naltrexone into practice for what reasons, and what clinical and nonclinical factors acted as barriers to its use. In our mail survey of alcoholism treatment clinicians, 80% of physicians and 45% of nonphysicians report prescribing or recommending naltrexone at least rarely, but only 15% of physicians, even among addiction specialists, prescribe naltrexone often. The strongest barriers to adoption of naltrexone were financing and inadequate knowledge about the medication, followed by lack of sufficient evidence regarding effectiveness. Clinicians were most likely to adopt naltrexone if they were affiliated with treatment programs that actively promoted its use. We conclude that in order for a new substance abuse treatment medication to be widely adopted in clinical practice, information about it must be properly directed, clinicians must be convinced of its effectiveness, it must be adequately financed, and the treatment organizations in which clinicians work must promote its use.

KW - Alcoholism treatment

KW - Diffusion

KW - Medication

KW - Naltrexone

KW - Prescribing

UR - http://www.scopus.com/inward/record.url?scp=0037223822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037223822&partnerID=8YFLogxK

U2 - 10.1016/S0740-5472(02)00319-7

DO - 10.1016/S0740-5472(02)00319-7

M3 - Article

VL - 24

SP - 1

EP - 11

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

IS - 1

ER -